We are here for the people we serve in their pursuit of healthy lives. This has been the way of Abbott for more than a century—passionately and thoughtfully translating science into lasting contributions to health.
Our products encircle life, from newborns to aging adults, from nutrition and diagnostics through medical care and pharmaceutical therapy.
Caring is central to the work we do and defines our responsibility to those we serve.
We advance leading-edge science and technologies that hold the potential for significant improvements to health and to the practice of healthcare.
We value our diversity—that of our products, technologies, markets and people—and believe that diverse perspectives combined with shared goals inspire new ideas and better ways of addressing changing health needs.
We focus on exceptional performance—a hallmark of Abbott people worldwide—demanding of ourselves and each other because our work impacts people’s lives.
We strive to earn the trust of those we serve by committing to the highest standards of quality, excellence in personal relationships, and behavior characterized by honesty, fairness and integrity.
We sustain success—for our business and the people we serve—by staying true to key tenets upon which our company was founded over a century ago: innovative care and a desire to make a meaningful difference in all that we do.
The promise of our company is in the promise that our work holds for health and life.

Research Grants 157 show all


$122.4K
2014

$180.5K
2015

$820.7K
2016

$912.3K
2017

$863.5K
2018

Publications 4,638 show all

  • 114
    Enzyme Inhibitors/pharmacology
  • 67
    Drug Design
  • 61
    Anti-Bacterial Agents/pharmacology
  • 60
    Chromatography, High Pressure Liquid/methods
  • 58
    Enzyme Inhibitors/chemical synthesis
  • 51
    Pyridines/pharmacology
  • 50
    Erythromycin/analogs & derivatives
  • 48
    Renin/antagonists & inhibitors
  • 46
    Hydroxyurea/analogs & derivatives
  • 42
    Histamine Antagonists/pharmacology

Patents 42,512show all

  • 5,834
    C07D - Heterocyclic compounds
  • 5,292
    A61K - Preparations for medical, dental, or toilet purposes
  • 4,278
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 2,964
    A61B - Diagnosis
  • 2,860
    A61M - Devices for introducing media into, or onto, the body
  • 2,611
    C07K - Peptides
  • 2,326
    A61F - Filters implantable into blood vessels
  • 1,773
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 1,738
    C07C - Acyclic or carbocyclic compounds
  • 1,675
    A23L - Foods, foodstuffs, or non-alcoholic beverages, not covered by subclasses  -

Clinical Trials 1,483show all

482N/A275Phase 3172Phase 2155Phase 4108Phase 145Other

SEC Filings show all


224
8-K

78
10-Q

23
10-K

4
D

Contact Information

Lake Bluff, IL
United States

SEC Form D Funding Events

DateOfferedSoldType
2011-03-15$100,000$100,000Debt
2010-03-12$70,000$70,000Debt
2009-03-13$6,690,000$6,690,000Debt
2008-03-17Unknown Unknown Other (Paper Filing)

Key Executives

  • Miles D. White
    Executive Officer
  • Richard W. Ashley
    Executive Officer
  • John M. Capek
    Executive Officer
  • Thomas C. Freyman
    Executive Officer
  • Holger A. Liepmann
    Executive Officer
  • Edward L. Michael
    Executive Officer
  • Laura J. Schumacher
    Executive Officer
  • James L. Tyree
    Executive Officer
  • Olivier Bohuon
    Executive Officer
  • Thomas F. Chen
    Executive Officer
  • Stephen R. Fussell
    Executive Officer
  • Robert B. Hance
    Executive Officer
  • John C. Landgraf
    Executive Officer
  • Greg W. Linder
    Executive Officer
  • Heather L. Mason
    Executive Officer
  • James V. Mazzo
    Executive Officer
  • Donald V. Patton Jr.
    Executive Officer
  • Mary T. Szela
    Executive Officer
  • Michael J. Warmuth
    Executive Officer
  • Robert J. Alpern
    Director
  • Roxanne S. Austin
    Director
  • William M. Daley
    Director
  • W. James Farrell
    Director
  • H. Laurance Fuller
    Director
  • William A. Osborn
    Director
  • David A. L. Owen
    Director
  • Boone Powell Jr.
    Director
  • W. Ann Reynolds
    Director
  • Roy S. Roberts
    Director
  • Samuel C. Scott III
    Director
  • William D. Smithburg
    Director
  • Glenn F. Tilton
    Director
  • Carlos Alban
    Executive Officer
  • J. Scott White
    Executive Officer
  • David A.l. Owen
    Director
  • Richard A. Gonzalez
    Executive Officer
  • Brian J. Blaser
    Executive Officer
  • A. David Forrest
    Executive Officer
  • Edward M. Liddy
    Director
  • Phebe N. Novakovic
    Director